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Abstract
Objective
Morphine is a commonly used drug in encephalopathic neonates treated with therapeutic
hypothermia after perinatal asphyxia. Pharmacokinetics and optimal dosing of morphine in
this population are largely unknown. The objective of this study was to describe pharmacoki-
netics of morphine and its metabolites morphine-3-glucuronide and morphine-6-glucuronide
in encephalopathic neonates treated with therapeutic hypothermia and to develop pharma-
cokinetics based dosing guidelines for this population.
Study design
Term and near-term encephalopathic neonates treated with therapeutic hypothermia and
receiving morphine were included in two multicenter cohort studies between 2008–2010
(SHIVER) and 2010–2014 (PharmaCool). Data were collected during hypothermia and
PLOS ONE | https://doi.org/10.1371/journal.pone.0211910 February 14, 2019 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Favie´ LMA, Groenendaal F, van den Broek
MPH, Rademaker CMA, de Haan TR, van Straaten
HLM, et al. (2019) Pharmacokinetics of morphine
in encephalopathic neonates treated with
therapeutic hypothermia. PLoS ONE 14(2):
e0211910. https://doi.org/10.1371/journal.
pone.0211910
Editor: Markos Leggas, University of Kentucky,
UNITED STATES
Received: September 14, 2018
Accepted: January 22, 2019
Published: February 14, 2019
Copyright: © 2019 Favie´ et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files. Additionally, the dataset used for the analyses
are available in the Dryad Digital Repository at
doi:10.5061/dryad.m8v146p.
Funding: Funding for this study was received from
the Netherlands Organization for Health Research
and Development (ZonMw) Priority Medicines for
Children (grant number: 40-41500-98-9002). The
funder did not play a role in the study design, data
rewarming, including blood samples for quantification of morphine and its metabolites.
Parental informed consent was obtained for all participants.
Results
244 patients (GA mean (sd) 39.8 (1.6) weeks, BW mean (sd) 3,428 (613) g, male 61.5%)
were included. Morphine clearance was reduced under hypothermia (33.5˚C) by 6.89%/˚C
(95% CI 5.37%/˚C– 8.41%/˚C, p<0.001) and metabolite clearance by 4.91%/˚C (95% CI
3.53%/˚C– 6.22%/˚C, p<0.001) compared to normothermia (36.5˚C). Simulations showed
that a loading dose of 50 μg/kg followed by continuous infusion of 5 μg/kg/h resulted in mor-
phine plasma concentrations in the desired range (between 10 and 40 μg/L) during
hypothermia.
Conclusions
Clearance of morphine and its metabolites in neonates is affected by therapeutic hypother-
mia. The regimen suggested by the simulations will be sufficient in the majority of patients.
However, due to the large interpatient variability a higher dose might be necessary in individ-
ual patients to achieve the desired effect.
Trial registration
www.trialregister.nl NTR2529.
Introduction
Hypoxic-ischemic encephalopathy (HIE) following perinatal asphyxia is one of the leading
causes of death and disability in term and near term neonates. Therapeutic hypothermia (TH,
lowering the core temperature to 33–34˚ C for 72h) is an established neuroprotective strategy
and has become standard of care for these patients in developed countries.[1,2] In the Nether-
lands, approximately 150–200 neonates receive this treatment annually using whole-body
cooling.[3]
Morphine is a commonly used drug in hypothermic neonates to provide analgesia and
sedation, and is considered an important drug since stress may reduce the neuroprotective
effects of TH.[4] Morphine undergoes extensive hepatic metabolism and its predominant
metabolite is morphine-3-glucuronide (M3G) which is non-sedative. The less abundant
metabolite morphine-6-glucuronide (M6G) is pharmacologically active with similar or greater
sedative and analgesic effects compared to the parent compound.[5,6] Both glucuronide
metabolites are formed by UDP glucuronosyltransferase 2B7 (UGT2B7).[5] The UGT2B7
enzyme activity in neonates is less than 10% of that in adults, but increases rapidly during the
first days after birth.[7,8] Both metabolites are eliminated through the kidneys.[5] At birth,
renal function is underdeveloped compared to older children and adults. In the first few weeks
of life, a steady increase in renal function can be seen.[8] Thus, maturation of kidney function
might influence metabolite elimination.[8,9]
Hypothermia might influence numerous physiological processes involved in drug metabo-
lism. Hypothermia reduces cardiac output and increases vascular resistance, which leads to
decreased liver perfusion. Decreased liver perfusion might result in decreased drug clearance,
especially in drugs with a high hepatic extraction ratio. Furthermore, the activity of liver
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enzymes such as cytochrome P450 and UGT27B can be declined during TH resulting in
impaired clearance. Likewise, TH can decrease renal drug clearance by reducing kidney perfu-
sion and subsequent glomerular filtration but also through changes in tubular secretion and
reabsorption.[10–12] Additionally, pharmacokinetics (PK) of drugs administered to these neo-
nates may be altered due to hypoxia-ischemia related multi-organ failure.[13,14] In recent
years, studies have been conducted that investigated the PK of frequently used drugs in neo-
nates undergoing TH. The findings of these studies have led to dose recommendations for sev-
eral antibiotics and anticonvulsive drugs.[15–21]
Morphine PK in normothermic neonates has been investigated in several studies, mostly
involving preterm and term neonates following major thoracic and abdominal surgery.[22]
Neonates with a postnatal age (PNA) below 10 days had a markedly reduced morphine clear-
ance compared to older children which has been attributed to impaired glucuronidation. This
effect was independent of birth weight (BW) or gestational age (GA). Maintenance dose in this
group was reduced by 50% compared to older children to achieve morphine plasma concen-
trations between 10 and 40 μg/L.[9] This dosing algorithm has been prospectively validated
and body weight has been shown to accurately predict morphine clearance across the entire
pediatric population.[23–25]
Morphine PK in neonates with HIE undergoing TH has only sparsely been investigated.
Ro´ka et al. (2008) found elevated morphine plasma concentrations in neonates treated with
TH (N = 10) compared to non-asphyxiated normothermic controls (N = 6) with similar infu-
sion rates and cumulative doses.[26] Frymoyer et al. (2016) developed a population PK model
for morphine, M3G and M6G during TH using data from 20 neonates. They concluded that
morphine clearance during TH was lower compared to previous studies in normothermic
asphyxiated neonates and advised a loading dose of 50 μg/kg followed by 5 μg/kg continuous
infusion.[27] Both studies did not include data during and after rewarming. Additional char-
acterization of morphine PK using a larger dataset is imperative to guide clinicians in the
application of this widely used and important drug in this critically ill population.
The objective of the present study was to describe the PK of morphine and its metabolites
in neonates with HIE both during and after TH using nonlinear mixed effect modelling and to
develop pharmacokinetics based dosing guidelines based on a large dataset obtained from two
multicenter studies conducted in the Netherlands and Belgium.
Patients and methods
Setting, study design and study population
The open label prospective SHIVER study was performed in the tertiary neonatal intensive
care units (NICU) of the University Medical Center Utrecht, Utrecht and Isala Clinics, Zwolle.
The open label prospective PharmaCool study was conducted in twelve tertiary NICUs in the
Netherlands and Belgium.[28] In both studies, term neonates undergoing TH for HIE were eli-
gible for inclusion. According to national treatment protocol, neonates with a GA between
36.0 and 42.0 weeks were cooled within 6 hours after birth to a core temperature of 33.5˚C
(accepted range 33.0–34.0˚C) for 72 hours. Thereafter, patients were slowly (0.4˚C/hour)
rewarmed to normothermia (36.5˚C). After rewarming, body temperature was stabilized at
36.5˚C for 24 hours.[3] Exclusion criteria were severe congenital malformations, encephalopa-
thy due to other causes than perinatal asphyxia and the absence of central venous or arterial
access for non-invasive blood sampling. From each included patient, written parental
informed consent was obtained. Inclusion took place between 2008–2010 (SHIVER) and
2010–2014 (PharmaCool). In total, 339 patients were screened and 277 included. For the pres-
ent study, neonates participating in either study and receiving intravenous morphine were
Morphine pharmacokinetics in hypothermic neonates
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selected. Data analysis was completed in 2018. The SHIVER study was approved by the Institu-
tional Review Board (IRB) of the University Medical Center Utrecht (no. 08/404) and subse-
quently approved by the IRB of the Isala Clinics, Zwolle. The PharmaCool study was approved
by the IRB of the Academic Medical Center Amsterdam (no. 10/255) and subsequently
approved by the IRBs of the VU Medical Center Amsterdam, University Medical Center
Utrecht, Leiden University Medical Center, Erasmus Medical Center Rotterdam, Maxima
Medical Center Veldhoven, Maastricht University Medical Center, Radboud University Medi-
cal Center Nijmegen, Isala Clincs Zwolle, University Medical Center Groningen, University
Hospital Gent and University Hospital Brussels.
Morphine dosing and administration
In both studies, morphine was administrated as morphine hydrochloride according to local
protocols and/or the attending physician’s discretion as an intravenous continuous infusion,
often preceded by a loading dose. Morphine was generally started at the onset of TH or shortly
before. Dose adjustments, including administration of any additional loading dose, were based
on each patient’s clinical condition and were not influenced by the study protocol.
Pharmacokinetic sampling and bioanalysis
From all patients, 1 ml blood samples were obtained from an indwelling catheter on four con-
secutive days, both during hypothermia and rewarming/normothermia. Sampling was sched-
uled at designated time points at 24 hours intervals. This limited sampling strategy was
designed to minimize patient risk while still obtaining sufficient information to achieve the
study objective. In the SHIVER study, residual material from blood samples taken for clinical
care were available for some patients. Plasma concentrations of morphine, M3G and M6G
were determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The
lower limit of quantification (LLQ) was 10 μg/L for morphine and M3G and 5 μg/L for M6G.
The calibration curves were linear from 10 to 1000 μg/L for morphine, 10 to 600 μg/L for M3G
and 5 to 200 μg/L for M6G. Between-run and within-run coefficients of variation were<5%
for morphine and M3G and<8% for M6G. Samples were stored at -80˚C until analyses at the
Clinical Pharmaceutical and Toxicological Laboratory of the Department of Clinical Pharmacy
of the University Medical Center Utrecht, the Netherlands.
Population pharmacokinetic analysis
A population pharmacokinetic model was developed from morphine, M3G, and M6G concen-
tration–time data using the nonlinear mixed effect modelling program NONMEM (version
7.3, Icon Development Solutions) with R (version 3.4.1), Xpose (version 4) for data visualiza-
tion and Piraña for run management.[29] Morphine hydrochloride (molecular weight (MW)
321.8 g/mol) doses were converted to morphine base (MW 285.3 g/mol) and consecutively, all
units of dose and concentration for morphine, M3G and M6G (MW 461.5 g/mol) were con-
verted to μmol and μmol/L, respectively for the purpose of the pharmacokinetic analysis. BW
was used as a descriptor for body size in our population and was related to pharmacokinetic
parameters using allometric relationships. The exponent defining the relationship of BW and
clearance (Cl) was fixed to 0.75 and the exponent defining the relationship of BW and volume
of distribution (V) was fixed to 1. The fractions of morphine converted to the metabolite M3G
and M6G in neonates under hypothermia were unknown (FM3G and FM6G, respectively);
therefore, parameters relative to F were estimated (e.g. ClM3G/FM3G and VM3G/FM3G). Based
on previously published pharmacokinetic models of morphine in neonates[27,30], one- and
two-compartment models for morphine and subsequent one-compartment models for both
Morphine pharmacokinetics in hypothermic neonates
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metabolites were tested as a structural model. Morphine and metabolite data were fitted
simultaneously.
To study the effect of hypothermia on pharmacokinetics, a dynamic model of temperature
over time was included, which allowed prediction of the actual body temperature at each
moment of sampling. For all patients, the reported start and end times of TH were used to
determine the period of TH treatment. Body temperature during hypothermia was set at
33.5˚C, with consecutive rewarming at 0.4˚C/hour (i.e. rewarming time 7.5h) until 36.5˚C
after which body temperature was set to 36.5˚C for the remainder of the study time. Calculated
body temperature for each plasma sample was subsequently included in the PK model.
As renal function may be an important determinant for metabolite clearance and given that
renal function cannot be estimated from a single serum creatinine (SCr) measurement in neo-
nates, a model for SCr was developed using daily SCr values taken for clinical care from all
patients. In this model, the elimination rate of SCr was used as a surrogate marker for renal
function. PNA and GA were tested as covariates on both morphine and metabolite clearance.
Inclusion of covariates was guided by effect size, biological plausibility and statistical signifi-
cance (using the likelihood ratio test which assesses the difference in the NONMEM objective
function value (OFV), which is equal to minus twice the log likelihood, with a p-value of
<0.05 as cut-off for significance).
Interindividual variability (IIV) was modelled using a proportional model and tested on all
parameters. Covariance between IIV components was included based on physiological plausi-
bility and graphical exploration. A proportional error model was used to model residual unex-
plained variability. For each compound, separate error models were used. Parameter precision
was assessed with sampling importance resampling (SIR).[31] Internal validation of the final
model was evaluated by computing the normalized prediction distribution errors (NPDE,
1000 simulations).[32] Both graphical (e.g. goodness-of-fit plots, visual predictive check) and
statistical model evaluation procedures were used to assess model adequacy.
Dosing regimen development
Simulations were conducted to test four different dosing regimens using the parameter esti-
mates from the final pharmacokinetic model. To create the simulation dataset, the patient
characteristics of each neonate included in this study were replicated five times. Morphine
loading dose was simulated at PNA 4 hours, immediately followed by continuous infusion.
The following dosing regimens were evaluated, based on the current clinical practice: 1. load-
ing dose of 50 μg/kg followed by continuous infusion of 5 μg/kg/h; 2. loading dose of 50 μg/kg,
continuous infusion of 10 μg/kg/h; 3. loading dose of 100 μg/kg, continuous infusion of 5 μg/
kg/h; 4. loading dose of 100 μg/kg, continuous infusion of 10 μg/kg/h. The dynamic tempera-
ture model was used to introduce TH. For each neonate in the simulation dataset, TH (body
temperature of 33.5˚C for 72 hours) was simulated to start at PNA 5 hours, after which
rewarming commenced at 0.4˚C/hour. After rewarming, body temperature was fixed to
36.5˚C for the remainder of the simulations. Hourly plasma concentrations were predicted
until PNA 120 hours. Morphine plasma concentrations between 10 and 40 μg/L were consid-
ered effective and safe.
Results
Patient characteristics
For 244 neonates morphine dosing information and at least one morphine plasma concentra-
tion was available for analysis (Table 1). In general, loading doses between 50 and 100 μg/kg
were given, followed by continuous infusion with doses varying between 5 and 25 μg/kg/h.
Morphine pharmacokinetics in hypothermic neonates
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A total of 853 blood samples were analyzed (median 4 samples per patient, range 1–11).
Samples with measurements below LLQ for all compounds (n = 23) were excluded from fur-
ther analyses, leaving 830 viable samples. Of these, 550 (66.3%) were drawn during the hypo-
thermic phase. For 18 patients (7.4%), only one sample was available. Plasma concentrations
for morphine varied between 10.0 and 371.2 μg/L (Fig 1); for M3G between 11.0 and 930.6 μg/
L and for M6G between 5.1 and 211.2 μg/L (S1 Fig). In one patient (0.41%), morphine plasma
concentrations exceeding 300 μg/L were reached.
Population pharmacokinetic analysis
A one-compartment model for morphine and subsequent one-compartment models for both
metabolites provided the best fit for the data. Pharmacokinetic parameter estimates of the final
model are shown in Table 2.
Introduction of a peripheral compartment for morphine resulted in an unstable model with
unrealistic intercompartmental clearance. GA and PNA were identified as covariates on mor-
phine clearance (GA: p<0.001, PNA: p<0.001), but not on metabolite clearance. Morphine
clearance was increased by 50.4% at PNA 5 days, compared to birth (increase of 0.42%/h, 95%
CI 0.297%/h– 0.582%/h); at birth, morphine clearance in a neonate with GA 36 weeks was
46% lower compared to GA 40 weeks, while clearance in a neonate with GA 42 weeks is 23%
higher (difference of 1.66%/d, 95%CI 1.30%– 1.94%). The elimination rate of SCr was intro-
duced as a covariate on the clearance of the metabolites as a measure of renal function. The
influence of this covariate was non-significant and therefore excluded from the final model.
Subsequently, the dynamic model of temperature over time was included as covariate on
Cl. The influence of body temperature on clearance was separated into an effect on ClMOR-
PHINE (a combination of hepatic and renal clearance) and CLMETABOLITES (renal clearance). As
Table 1. Patient characteristics.
Parameter Patients (N = 244)
Gestational age; wk, mean ± sd 39.8 ± 1.6
Birth weight; g, mean ± sd 3,428 ± 613
Birth weight� 2500 g; n (%) 16 (6.6%)
Male; n (%) 150 (61.5%)
pH�; median (IQR) 6.96 (6.80–7.09)
Base Excess�; mmol/L, median (IQR) -17 (-12.0 –-21.9)
Lactate�; mmol/L, median (IQR) 13.6 (9.0–18.2)
Thompson score#; median (IQR) 9.5 (8.0–12.0)
aEEG on admission#
Continuous normal voltage; n (%) 30 (12.3%)
Discontinuous normal voltage; n (%)
of whom< 5 μV; n (%)
102 (41.8%)
35 (14.3%)
Burst suppression; n (%) 58 (23.8%)
Continuous low voltage; n (%) 10 (4.1%)
Flat trace; n (%) 27 (11.1%)
Unknown; n (%) 17 (7.0%)
Mortality; n (%) 58 (23.8%)
sd = standard deviation, IQR = interquartile range
�Value measured in umbilical cord blood or, if unavailable, from arterial or venous blood within 1h after birth
#Encephalopathy was characterized by a Thompson score of >7 1h after birth or an abnormal aEEG on admission to
a level III NICU
https://doi.org/10.1371/journal.pone.0211910.t001
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Fig 1. Observed morphine plasma concentrations (μg/L). Dotted lines indicate the proposed therapeutic window of
10–40 μg/L; solid line indicates the potentially toxic limit of 300 μg/L.
https://doi.org/10.1371/journal.pone.0211910.g001
Table 2. Final model pharmacokinetic parameter estimates and SIR results.
Morphine M3G§ M6G§
Parameter Estimate SIR� 95% CI Estimate SIR� 95% CI Estimate SIR� 95% CI
Cl, l/h# 0.899 0.797–0.985 0.456 0.424–0.492 1.73 1.61–1.87
V, l# 8.88 7.87–9.92 0.264 0.089–0.384 4.53 3.64–5.39
PNA on Cl; %/h 0.420 0.297–0.582 NA NA NA NA
GA on Cl; %/d 1.66 1.30–1.94 NA NA NA NA
TEMP on Cl; %/˚C 6.89 5.37–8.41 4.91$ 3.53–6.22$ 4.91$ 3.53–6.22$
Interindividual variability
Cl, variance (rsd) 0.224 (47.3%) 0.185–0.276 0.291$ (53.9%) 0.240–0.356$ 0.291$ (53.9%) 0.240–0.356$
V, variance (rsd) 0.464 (68.1%) 0.364–0.602 NA NA NA NA
Covariance interindividual variability Clmorphine/Clmetabolites
Covariance (correlation coefficient) 0.117 (46.0%) 0.0799–0.161
Residual variability
Proportional, variance (rsd) 0.0498 (22.3%) 0.0437–0.0574 0.0914 (30.2%) 0.0798–0.105 0.101 (31.8%) 0.0888–0.115
Final model
ClMORPHINE = 0.899 x (BW/3.5)
0.75 x (1 + 0.0042 x PNA) x (1 + 0.0166 x (GA-280)) x (1 + 0.0689 x (TEMP-36.5))
VMORPHINE = 8.88 x (BW/3.5)
1
ClM3G/FM3G = 0.456 x (BW/3.5)
0.75 x (1 + 0.0491 x (TEMP-36.5)
VM3G/FM3G = 0.264 x (BW/3.5)
1
ClM6G/FM6G = 1.73 x (BW/3.5)
0.75 x (1 + 0.0491 x (TEMP-36.5)
VM6G/FM6G = 4.53 x (BW/3.5)
1
§All metabolite estimates are relative to formation fraction FM3G and FM6G, resp.
�Ten iterations; no. of samples 1000,1000,1000,1000,1000,1000,2000,2000,2000,2000; no. of resamples 200,200,400,400,500,500,1000,1000,1000,1000
#Estimates for neonate with BW 3.5 kg, GA 280 days, PNA 0h and TEMP 36.5˚C
$Single estimate for both metabolites
V = volume of distribution, Cl = clearance, PNA = postnatal age, GA = gestational age, TEMP = body temperature, M3G = morphine-3-glucuronide, M6G = morphine-
6-glucuronide, SIR = sampling importance resampling, BW = birth weight, NA = not applicable, rsd = relative standard deviation
https://doi.org/10.1371/journal.pone.0211910.t002
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the effect of body temperature on M3G and M6G clearance were similar and separate effects
for both metabolites did not improve model performance, this was estimated as a single effect
in the final model. Morphine clearance during hypothermia was decreased by 20.7%
(p<0.001, 6.89%/˚C, 95% CI 5.37%/˚C– 8.41%/˚C) compared to normothermia. Metabolite
clearance during hypothermia was decreased by 14.7% (p<0.001, 4.91%/˚C, 95% CI 3.53%/
˚C– 6.22%/˚C).
The influence of BW, GA, PNA and temperature on the average morphine clearance is pre-
dicted by the final model are depicted in Fig 2.
Model evaluation demonstrated that the final model was adequate in describing the data.
Goodness-of-fit plots of observed versus population and individual predicted concentrations
showed no systematic deviation and the weighted residuals were homogeneously scattered for
both parent and metabolites (S2–S4 Figs). NPDE plots for morphine, M3G and M6G indicate
that the NPDE follows the normal distribution and that the model does not contain major bias
(S5–S7 Figs).
Dosing regimen
Morphine plasma concentrations after various dosing regimens were predicted using a simula-
tion dataset of 1220 patients and the final PK parameter estimates. In all simulations, mor-
phine clearance was markedly influenced by PNA and TH. Immediately after rewarming,
average morphine clearance was increased by 63.4% compared to clearance at the start of TH.
Of this increase, 29.6% could be attributed to an effect of PNA. A maintenance dose of 5 μg/
kg/h preceded by a loading dose of 50 μg/kg resulted in plasma concentrations between 10 and
40 μg/L at PNA 12h in 88.2% of patients, while 7.8% of patients were below 10 μg/L and 4.0%
above 40 μg/L. At PNA 48h, morphine plasma concentration exceeded 40 μg/L in 6.8% of
patients. As clearance is not constant but increased over time, no steady state in morphine
plasma concentration was reached in the first five days of life. At PNA 77 hours, TH was
stopped resulting in an additional increase in clearance and drop in plasma concentration (Fig
3). Plasma concentrations for both metabolites accumulated during TH but reached steady
state once clearance increased under normothermic conditions (S8 Fig). Morphine plasma
concentrations for the other simulated dosing regimens are included as a supplement (S9 Fig).
Fig 2. Average predicted morphine clearance over time before, during and after TH for neonates with BW 3.5 and GA 36, 38, 40 and 42 weeks,
respectively (left) and for neonates with GA 40 weeks and BW 2.5, 3.0, 3.5 and 4.0 kg, respectively (right). Solid vertical lines represent the start and end of
TH (33.5˚C) simulated between 5h and 77h after birth; dashed vertical line indicates the return to normothermia (36.5˚C) with rewarming simulated at. 0.4˚C/
h; TH = therapeutic hypothermia, BW = birth weight GA = gestational age.
https://doi.org/10.1371/journal.pone.0211910.g002
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Discussion
This study combining data from two large multicenter studies shows that clearance of both
morphine and its metabolites is reduced during hypothermia in neonates with HIE compared
to normothermia. Furthermore, the impact of BW, GA and PNA on the PK of morphine and
its metabolites has been quantified. Reduction in clearance during TH is most likely caused by
a decrease in perfusion of the liver and kidneys. Additionally, an effect of TH on activity of
UGT2B7, the enzyme responsible for metabolizing morphine into M3G and M6G, might
explain why morphine clearance is more strongly affected than metabolite clearance.
Although a therapeutic window for morphine plasma concentrations has not been firmly
established, especially in neonates undergoing TH, the best available evidence suggests a pre-
ferred range between 10 and 40 μg/L, while levels above 300 μg/L have been associated with
respiratory depression and prolonged mechanical ventilation.[25,33–38] Based on the simula-
tions performed in this study, a starting dose of 50 μg/kg followed by 5 μg/kg/h is recom-
mended to achieve morphine plasma concentrations between 10 and 40 μg/L, although the
large interpatient variability (47.3% for Cl and 68.1% for V, Table 2) might lead to higher
(>40 μg/l) plasma concentrations in individual patients. Contrarily, a higher morphine dose
may be needed in some patients to ensure effective treatment. Clinicians should not be
Fig 3. Simulated morphine plasma concentrations of the proposed dosing regimen of 5 μg/kg/h after loading dose
of 50 μg/kg. Solid line indicates the mean morphine plasma concentration; gray area represents the 95% prediction
interval. Dotted horizontal lines indicate the proposed therapeutic window of 10–40 μg/L. Solid vertical lines indicate
the start and end of TH (33.5˚C) simulated between 5h and 77h after birth; dashed vertical line indicates the return to
normothermia (36.5˚C) with rewarming simulated at 0.4˚C/h; TH = therapeutic hypothermia.
https://doi.org/10.1371/journal.pone.0211910.g003
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reluctant to increase the maintenance dose if the starting dose proves inadequate for a patient’s
clinical condition both during and, if morphine is not stopped simultaneously with TH, after
hypothermia.
The current practice rarely leads to plasma concentrations exceeding the potentially toxic
upper limit of 300 μg/L, but may lead to unnecessary high morphine exposure. Neonatal opi-
oid use has been associated with impaired cognitive and behavioral development in animal
studies.[39] Long term follow-up studies in humans suggest a possible negative effect in early
childhood that does not persist later in life.[40–43] Conversely, adequate management of pain
and discomfort is needed to improve recovery, to ensure the effectiveness of TH and to prevent
adverse physiological responses such as changes in intrathoracic or arterial pressure and vaso-
constriction of vital organs.[4,38,39]
Morphine PK was best described using a one-compartment model for morphine and subse-
quent one-compartment models for each of the glucuronide metabolites. Previously, PK of the
parent compound has been adequately described using both one-compartment[44,45] and
two-compartment models.[9,23,27] A recently published meta-model combining data
obtained in neonates and older children from five separate studies proposed a one-compart-
ment model for morphine PK.[30] Metabolite PK was adequately described using one-com-
partment models for each metabolite in all studies.[9,23,27,44] Parameter estimates from this
model extrapolated to a neonate with GA 40 weeks and BW 3.5 kg result in a higher morphine
clearance (1.54 l/h) and a lower volume of distribution (5.25 l) compared to our findings.[30]
This might be explained by the fact that our patient population consisted of critically ill term
neonates admitted to a NICU. The meta-model incorporated data form both term and preterm
neonates and from older children and adults as well. In all included studies, morphine was
administered for post-operative pain. Morphine parameter estimates reported in a small data-
set by Frymoyer et al. in the same population are in accordance with our findings, despite the
differences in the underlying PK model (Cl 0.765 l/h, V 8.02 l).[27] Also, the impact of TH on
morphine clearance in our study is similar to the effect found by Ro´ka et al., who compared
hypothermic neonates to non-asphyxiated normothermic controls using a non-parametric
approach (Cl 0.69 l/h vs 0.89 l/h, decrease of 22.5%).[26]
GA was identified as a significant covariate on morphine clearance despite the relatively
narrow range of GA (36–42 weeks) in this population. Previous reports investigating the PK of
other drugs in the PharmaCool study population have reported similar effects.[18–20] In the
present study, this might be explained by a lower baseline UGT2B7 activity in neonates with a
lower GA. However, due to the large interpatient variability, this finding did not translate into
a dosing advise differentiated by GA. For each of the situations presented in Fig 2, the simu-
lated dosing regimen yields average morphine plasma concentrations between 10 and 40 μg/L.
The majority of patients included in this study had a GA between 38 and 41 weeks (202/244,
82.8%); a lower mg/kg dose for neonates with a GA of 36 and 37 weeks only marginally
improved the fraction of patients within the therapeutic window at PNA 12 hours. Further-
more, a differentiated dosing regimen based on GA within this relatively small subpopulation
of NICU patients is deemed undesirable as this will be error-prone. Therefore, the proposed
dosing regimen is advised for all neonates treated with TH after HIE. Currently, TH is
explored in preterm neonates (GA 34–35 weeks) as well.[46] Extrapolation of our results to
these neonates should be done with caution due to the absence of this patient population in
the current dataset.
Our data show an increase in morphine clearance during the first five days after birth. This
effect could be identified independently of the effect of body temperature. The increase of
clearance over time can be attributed to maturation of UGT2B7. Maturation of this enzyme in
normothermic neonates has been described for morphine but also for other drugs
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predominantly glucuronidated by UGT2B7.[9,47–50] Recovery of organ function after perina-
tal asphyxia might also play a role in this observed increase in clearance during the first days of
life. During asphyxia, the liver is deprived of oxygen, resulting in hepatocyte damage. Alanine
aminotransferase (ALAT) and aspartate aminotransferase (ASAT) levels are commonly used
to indicate hepatocyte damage and both are frequently elevated in neonates with HIE. Peak
levels are reached within 72 hours and normalize within the first two weeks of life, indicating
recovery of liver function in this timeframe.[51–53] Unfortunately, ALAT and ASAT are poor
predictors for hepatic drug metabolism and cannot be reliably used to predict hepatic clear-
ance. Therefore, it was not possible to distinguish between enzyme maturation and recovery of
liver damage.
Introducing temperature as a continuous covariate allowed for a more precise estimate of
the effect of body temperature on the pharmacokinetics of morphine and its metabolites since
also samples during rewarming were available. Additionally, including temperature as a
dichotomous covariate proved to be a less adequate fit for the data. Some assumptions had to
be made for this dynamic model. Firstly, we assumed that the average body temperature of
each neonate during TH was 33.5˚C and that possible fluctuations between 33.0 and 34.0˚C
would have a negligible effect. Body temperature during TH was therefore fixed to 33.5˚C. Sec-
ondly, we assumed that rewarming for each neonate occurred according to national protocol
at 0.4˚C/hour. In clinical practice, rewarming is sometimes slowed or halted if seizures occur
during rewarming. As this information was not available in our dataset, rewarming for each
neonate was set at 0.4˚C/hour. Thirdly, as body temperature after TH is stabilized at 36.5˚C
for 24 hours, we opted for a fixed body temperature of 36.5˚C for each neonate after rewarm-
ing. As morphine is primarily administrated to prevent stress during hypothermia and is often
stopped with or shortly after TH, we believe that this assumption is an accurate representation
of clinical practice. Lastly, we assume a linear effect between body temperature and clearance
and therefore report and effect per˚C. Although we have no evidence for non-linearity, the
limited sampling strategy was insufficient to exclude this. However, in event of non-linearity,
the reported effect is an average effect per˚C between 33.5 and 36.5˚C and does not alter the
overall effect of TH on clearance.
SCr is a specific marker for renal function and is widely used in adults to predict reduced
clearance of renally excreted drugs. In neonates, SCr levels in the first few days of life are con-
founded by maternal SCr levels due to maternal transfer. We considered a dynamic model of
SCr over time a better predictor of changes in renal function. No relationship between serum
creatinine and renal clearance of the metabolites could be identified. Additionally, increased
metabolite clearance over time in the first five days of life could not be observed. This effect
was found in the same population for amoxicillin and benzylpenicillin, drugs that are predom-
inantly excreted renally in unmetabolized form.[18,20] Data collection up to five days after
birth might have been too short to detect maturation of renal function since steady state M3G
and M6G plasma concentrations are not reached during hypothermia (S8 Fig). Also, as matu-
ration of renal function in the first few days after birth occurs simultaneously with TH, the
effect of maturation on metabolite clearance might not be distinguishable from the effect of
hypothermia.
Pharmacodynamics (PD) end points of morphine were not incorporated in the final model.
Although the COMFORT-B score, as indicator for pain and stress, was routinely recorded in
this population, the timing of this score in relation to morphine dosing was often unclear. Pain
expression in hypothermic neonates differs from normothermic neonates, making it uncertain
whether the COMFORT-B score is suitable for treatment evaluation in this population.
[38,54,55] Additionally, this scale has not been developed to distinguish between adequate
treatment effect (eg. adequate sedation) and supratherapeutic effects (eg. oversedation).
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Strengths of this study are the large number of included patients recruited from twelve ter-
tiary NICUs in two countries, making this study population representative for all neonates
treated with TH after HIE. The dosing regimen advised in this study corresponds with the dos-
ing advise postulated by Frymoyer et al.[27] Reconstructing the full profile of hypothermia
and rewarming enabled us to accurately assess the influence of body temperature on clearance.
In all participating centers, TH is applied using a uniform cooling device and with a joint treat-
ment protocol, thereby decreasing the chance of treatment variation.[3]
Limitations are the lack of PD end points associated with morphine. Clinicians are insuffi-
ciently supported by robust tools to facilitate morphine dose adjustments. Development and
validation of such an instrument should be the focus of future research. Subsequently, this tool
could be used to prospectively validate our dosing regimen. Ideally, future PD studies will also
incorporate M6G plasma concentrations for determining exposure-response as the contribu-
tion of this active metabolite to the effects attributed to morphine in neonates are largely
unknown.
For ethical reasons, it was not possible to answer this research question using a prospective
randomized controlled trial comparing hypothermic with non-hypothermic patients. Also,
comparison to an adequate historical control group is not feasible as morphine nor metabolite
plasma concentrations are available from before 2008.
Conclusion
Clearance of morphine and its metabolites is reduced in neonates treated with TH for HIE.
Even though the current clinical practice only very rarely leads to morphine plasma concentra-
tions exceeding 300 μg/L, a relatively low starting dose of 50 μg/kg followed by continuous
infusion of 5 μg/kg/h is recommended in critically ill neonates treated with TH for HIE. How-
ever, due to the large interpatient variability, the uncertainty regarding the supposed therapeu-
tic window and the undesirable effect of discomfort in this population, a higher maintenance
dose may be required if the starting dose proves inadequate for the clinical condition of the
individual patient.
Supporting information
S1 Fig. observed plasma concentrations for M3G (left) and M3G (right).
M3G = morphine-3-glucuronde, M6G = morphine-6-glucuronide.
(TIF)
S2 Fig. Morphine goodness-of-fit plots. A = observed vs population predicted plasma con-
centrations; B = observed vs individual predicted plasma concentrations; C = population con-
ditional weighted residuals vs population predicted plasma concentrations; D = population
conditional weighted residuals vs time after birth; solid line indicates the linear regression line.
(TIF)
S3 Fig. M3G goodness-of-fit plots. A = observed vs population predicted plasma concentra-
tions; B = observed vs individual predicted plasma concentrations; C = population conditional
weighted residuals vs population predicted plasma concentrations; D = population conditional
weighted residuals vs time after birth; M3G = morphine-3-glucuronide; solid line indicates the
linear regression line.
(TIF)
S4 Fig. M6G goodness-of-fit plots. A = observed vs population predicted plasma concentra-
tions; B = observed vs individual predicted plasma concentrations; C = population conditional
weighted residuals vs population predicted plasma concentrations; D = population conditional
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weighted residuals vs time after birth; M6G = morphine-6-glucuronide; solid line indicates the
linear regression line.
(TIF)
S5 Fig. Normalized prediction distribution errors (NPDEs) of the final pharmacokinetic
model for morphine. A = kernel density plot of NPDE with a normal, Gaussian distribution
overlaid for comparative purposes; B = Q-Q plot of theoretical quantiles vs sample quantiles;
C = NPDE vs Time; D = NPDE vs predicted plasma concentrations; solid lines in figures C
and D represent the observed median, 5th and 95th percentiles, red box represent the predicted
90% confidence interval around the median, blue boxes represent the predicted 90% confi-
dence intervals around the 5th and 95th percentiles.
(TIF)
S6 Fig. Normalized prediction distribution errors (NPDEs) of the final pharmacokinetic
model for M3G. A = kernel density plot of NPDE with a normal, Gaussian distribution over-
laid for comparative purposes; B = Q-Q plot of theoretical quantiles vs sample quantiles;
C = NPDE vs Time; D = NPDE vs predicted plasma concentrations; M3G = morphine-3-glu-
curonide; solid lines in figures C and D represent the observed median, 5th and 95th percen-
tiles, red box represent the predicted 90% confidence interval around the median, blue boxes
represent the predicted 90% confidence intervals around the 5th and 95th percentiles.
(TIF)
S7 Fig. Normalized prediction distribution errors (NPDEs) of the final pharmacokinetic
model for M6G. A = kernel density plot of NPDE with a normal, Gaussian distribution over-
laid for comparative purposes; B = Q-Q plot of theoretical quantiles vs sample quantiles;
C = NPDE vs Time; D = NPDE vs predicted plasma concentrations; M6G = morphine-6-glu-
curonide; solid lines in figures C and D represent the observed median, 5th and 95th percen-
tiles, red box represent the predicted 90% confidence interval around the median, blue boxes
represent the predicted 90% confidence intervals around the 5th and 95th percentiles.
(TIF)
S8 Fig. simulated plasma concentration time profiles for M3G (left) and M6G (right) of
the proposed morphine dosing regimen of 5 μg/kg/h after loading dose of 50 μg/kg. Solid
line indicates the mean plasma concentration; gray area represents the 95% prediction interval.
M3G = morphine-3-glucuronde, M6G = morphine-6-glucuronide.
(TIF)
S9 Fig. Simulated morphine plasma concentrations of the dosing regimens of 10 μg/kg/h
after loading dose of 50 μg/kg (left), 5 μg/kg/h after loading dose of 100 μg/kg (center) and
10 μg/kg/h after loading dose of 100 μg/kg (right). Solid line indicates the mean morphine
plasma concentration; gray area represents the 95% prediction interval. Dotted horizontal
lines indicate the proposed therapeutic window of 10–40 μg/L. Solid vertical lines indicate the
start and end of TH (33.5˚C) simulated between 5h and 77h after birth; dashed vertical line
indicates the return to normothermia (36.5˚C) with rewarming simulated at 0.4˚C/h;
TH = therapeutic hypothermia.
(TIF)
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